8-K: Aquestive Secures $75M for Anaphylm Launch

Aquestive Therapeutics has secured a $75 million strategic funding agreement with RTW Investments LP to support the potential commercial launch of Anaphylm, contingent on FDA approval and debt refinancing.

Summary

• Aquestive Therapeutics, Inc. entered into a Purchase Agreement with funds managed by RTW Investments LP on August 13, 2025.
• The agreement provides $75 million in strategic funding to support the potential launch of Anaphylm (epinephrine) Sublingual Film.
• Funding is contingent upon FDA approval of Anaphylm, refinancing of the company's existing 13.5% Senior Secured Notes, and other customary conditions.
• RTW will receive tiered revenue share payments ranging from 7.5% to 1.0% of Net Sales of Anaphylm in the United States.
• A 9.5% revenue share applies for the subsequent calendar year period if Net Sales do not achieve a specified level in a calendar year period beginning in 2027.
• Revenue share payments will cease upon RTW's receipt of $187.5 million by December 31, 2035, or $225 million thereafter.
• The financing is expected to provide critical capital to support Aquestive Therapeutics through 2027.

Sentiment

Score: 8

Explanation: The securing of $75 million in strategic funding for a key pipeline asset (Anaphylm) is a significant positive development, strengthening the balance sheet and de-risking the commercialization pathway. While the funding is contingent and involves a revenue share, the overall impact is highly favorable for the company's near-term financial stability and product launch prospects.

Positives

• Secured $75 million in strategic funding, providing critical capital for the potential launch of Anaphylm.
• The financing is expected to strengthen the company's balance sheet and support operations through 2027.
• Partnership with RTW Investments, LP, a firm specializing in life sciences, reflects confidence in Anaphylm's commercial prospects.
• Anaphylm has the potential to be the first and only oral rescue medication for severe allergic reactions, offering a new, convenient treatment option for patients.

Negatives

• The funding agreement includes a tiered revenue share ranging from 7.5% to 1.0% (and potentially 9.5%) of future U.S. Net Sales, which will reduce the company's net revenue from Anaphylm.
• The total repayment cap of $187.5 million to $225 million represents a significant multiple of the initial $75 million funding.
• The availability of funds is contingent on two major conditions: FDA approval of Anaphylm and the refinancing of existing 13.5% Senior Secured Notes.
• The Purchase Agreement contains customary negative covenants, including restrictions on incurring additional indebtedness, until RTW achieves a specified return on its investment.

Risks

• Risks and uncertainties associated with FDA approval of Anaphylm.
• Risks related to refinancing the company's existing 13.5% Senior Secured Notes.
• Failure to satisfy customary closing conditions for the funding agreement.
• Delays or changes to the timing, cost, and success of product development activities and clinical trials for Anaphylm and AQST-108.
• Risk of not receiving FDA approval for any product candidates, including Anaphylm and AQST-108.
• Ability to generate sufficient clinical data for approval, including for pharmacokinetic and pharmacodynamic comparability for Anaphylm.
• Ability to address FDA's comments and concerns from Type C meeting minutes and filing review letter for Anaphylm, potentially requiring additional clinical studies.
• Risk that the FDA may require an Advisory Committee for Anaphylm approval.
• Delays in regulatory approval processes outside the U.S. (e.g., Canada, European Union) for Anaphylm.
• Success of competing products, including generics.
• Risks inherent in commercializing a new product, including technology, financial, market, implementation, and regulatory limitations.
• Risk of not having sufficient capital and cash resources to fund commercialization and future clinical development activities.
• Risk of eroding market share for Suboxone, which accounts for a substantial part of current operating revenue.
• Risk of default on debt instruments.
• Risks related to outsourcing sales, marketing, and other operational functions to third parties.
• Risk of the rate and degree of market acceptance of Anaphylm and other product candidates.
• Risks associated with intellectual property rights and infringement claims, including timely issuance of patents.
• Risk of legislation and regulatory actions affecting the business, product pricing, reimbursement, or access.
• Risks related to claims and legal proceedings, including patent infringement, securities, and product safety.
• Risks of product recalls and withdrawals.
• Risks related to disruptions in information technology networks and systems, including cybersecurity attacks.
• Risks related to adverse developments in the financial services industry, inflation, and rising interest rates.
• Impact of global pandemics (e.g., COVID-19) and geopolitical events (e.g., Ukraine and Israel wars) on business conditions.

Future Outlook

The company expects the strategic financing to provide critical capital to support operations through 2027, enabling the successful market launch of Anaphylm, if approved by the FDA. Anaphylm is anticipated to be the first and only oral rescue medication for severe allergic reactions, potentially transforming how patients carry and access their rescue medication. The company also continues to advance its earlier-stage epinephrine prodrug topical gel product candidate, AQST-108, for various dermatology conditions.

Management Comments

• "This financing provides critical capital that will support Aquestive Therapeutics through 2027, enabling us to successfully bring Anaphylm to market, if approved by the FDA, and deliver a new treatment option for patients in need." Dan Barber, Chief Executive Officer of Aquestive.
• "We continue to believe Anaphylm, potentially the first and only oral rescue medication for the treatment of severe allergic reactions, including anaphylaxis, can transform how patients carry and access their rescue medication." Dan Barber, Chief Executive Officer of Aquestive.
• "We are excited to support Aquestive, and todays investment reflects our belief in the commercial prospects of Anaphylm as a rescue treatment for patients experiencing a severe allergic reaction, including anaphylaxis." Roderick Wong, MD, Managing Partner and Chief Investment Officer of RTW Investments, LP.

Industry Context

This strategic funding agreement highlights a common financing strategy for pharmaceutical companies nearing commercialization of a key pipeline asset, especially for novel drug delivery systems like Aquestive's sublingual film technology. The focus on Anaphylm addresses a significant unmet medical need for a more convenient and accessible epinephrine auto-injector alternative for anaphylaxis, a market currently dominated by injectable devices. The partnership with a specialized life sciences investment firm like RTW Investments underscores the perceived commercial potential of such innovative solutions in the biopharmaceutical sector.

Stakeholder Impact

• Shareholders: Potential for increased value if Anaphylm is approved and successfully launched, as funding de-risks commercialization, but future revenue will be shared with RTW.
• Patients: Potential for a new, more convenient, and potentially life-saving oral treatment option for severe allergic reactions (Anaphylm).
• Creditors: The refinancing of existing 13.5% Senior Secured Notes is a condition, which will impact existing debt holders.

Next Steps

• Obtain FDA approval for Anaphylm (epinephrine) Sublingual Film.
• Refinance the company's existing 13.5% Senior Secured Notes.
• Satisfy other customary closing conditions for the Purchase Agreement.
• Commercialize Anaphylm in the United States, if approved.
• Continue clinical development of AQST-108 for dermatology conditions.

Key Dates

Recommendation

The strategic funding agreement provides critical capital for the potential launch of Anaphylm, a potentially transformative product. While contingent on FDA approval and debt refinancing, securing this non-dilutive financing significantly strengthens the company's balance sheet and de-risks the commercialization pathway, making it an attractive prospect for growth-oriented investors despite the future revenue share.

Keywords

Anaphylm, epinephrine, sublingual film, anaphylaxis, drug delivery, pharmaceuticals, biotechnology, strategic financing, FDA approval, RTW Investments, AQST